Findings

What do systematic reviews say?

3 questions · 3 findings · 3 reviews · Musculoskeletal

No studies found 1 · 33.3%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 33.3%High 1 · 33.3%

Total adverse events: number experiencing 24 weeks · Patients with osteoarthritis of the knee or hip

Paracetamol showed no clear difference in total adverse events: number experiencing 24 weeks compared with placebo (high certainty).

1 finding from 1 review

Paracetamol versus placebo for knee and hip osteoarthritis 2019 · Cochrane Headline outcomes only
RR 1.01 [0.92, 1.11]
8 studies · 3252 participants
High

Withdrawals due to adverse events · Patients with ankylosing spondylitis

Sulfasalazine probably leads to higher total number of withdrawals due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Sulfasalazine for ankylosing spondylitis 2014 · Cochrane Headline outcomes only
RR 1.43 [1.04, 1.94]
11 studies · 895 participants
Moderate

Total number of serious adverse events not measured · patients with osteoarthritis

The review found no eligible studies for this question.

1 finding from 1 review

Diacerein for osteoarthritis 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found